{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-060453","form_type":"8-K","ticker":null,"cik":"0001580063","company_name":"BIORA THERAPEUTICS, INC.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.058956+00:00","generated_at":"2026-06-01T23:04:32.093494+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Biora reports Q1 net loss $4.2M, completes BT-600 dosing, results expected late Q2","bullets":["Net loss $4.2M ($0.14/share) vs $17.4M ($1.59) in Q1 2023; operating expenses $16.1M.","BT-600 Phase 1 trial fully dosed; SAD data showed colon delivery and lower plasma levels than oral tofacitinib.","BioJet platform animal studies demonstrate >15% bioavailability; partnering process targeting mid-2024.","Capital raised $19.8M new investment since Dec 2023, reduced $80M notes; $6M direct placement closed April 2024.","Topline BT-600 data expected late June 2024; NaviCap device data presented at DDW May 19."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-060453","json":"https://secwatch.observer/filing/0000950170-24-060453.json","markdown":"https://secwatch.observer/filing/0000950170-24-060453.md","text":"https://secwatch.observer/filing/0000950170-24-060453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1580063/000095017024060453/0000950170-24-060453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1580063/000095017024060453/bior-20240515.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T23:04:32.093494+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"33351cfe49b97d170fbf3f521ab28806c585f8e2","claim":"BIORA THERAPEUTICS, INC. reported the first quarter ended March 31, 2024 results: net income Net loss was $4.2 million, EPS net loss per share was $0.14.","evidence_excerpt":"Biora Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1580063/000095017024060453/0000950170-24-060453-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the first quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss was $4.2 million"},{"label":"EPS","value":"net loss per share was $0.14"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}